<DOC>
	<DOCNO>NCT00511108</DOCNO>
	<brief_summary>A clinical study determine safety , efficacy mechanism action sitagliptin alone combination pioglitazone , patient type 2 diabetes mellitus inadequate glycemic ( blood sugar ) control .</brief_summary>
	<brief_title>Sitagliptin Pioglitazone Mechanism Action Study Type 2 Diabetes Mellitus ( 0431-061 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient type 2 diabetes mellitus Male Female highly unlikely become pregnant Patient antihyperglycemic agent ( AHA ) ( hemoglobin A1c [ A1C ] 710 % ) oral single AHA lowdose combination therapy ( A1C 6.59.0 % ) Patient history type 1 diabetes mellitus history ketoacidosis Patient require insulin therapy within past 12 week Patient take Peroxisome ProliferatorActivated Receptorgamma ( PPAR gamma ) agent ( i.e . Thiazolidinediones [ TZDs ] ) within prior 12 week screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus ( T2DM )</keyword>
</DOC>